Evidence map›Paper›PMID 27522115›Full record

ArticleJournal of autoimmunity2016

Human effector B lymphocytes express ARID3a and secrete interferon alpha.

Julie M Ward, Michelle L Ratliff, Mikhail G Dozmorov, Graham Wiley, Joel M Guthridge, Patrick M Gaffney, Judith A James, Carol F Webb

Open access · greenAbstract read
In one paragraph

Article in Journal of autoimmunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. CD4Lupus science & medicine · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Type-I interferons in atherosclerosis.The Journal of experimental medicine · 2020
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Metformin Inhibits the Type 1 IFN Response in Human CD4Journal of immunology (Baltimore, Md. : 1950) · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Julie M WardDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Michelle L RatliffDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Mikhail G DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
Graham WileyArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Joel M GuthridgeArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Patrick M GaffneyArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Judith A JamesDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Carol F WebbDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: carol-webb@ouhsc.edu.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USVirginia Commonwealth University · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Robert Hal Scofield · 2013 to 2026
$68.2M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Quantitative Analysis Core P30GM110766 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2014 to 2018
$6.1M
TNFAIP3 (A20) and Susceptibility to Systemic Lupus ErythematosusR01AR056360 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2009 to 2018
$6.0M
Molecular Basis of Immunity - Kirschtein-NRSAT32AI007633 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CUNNINGHAM, MADELEINE W. · 2001 to 2022
$4.0M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Bright Function in the Immune SystemR01AI044215 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI WEBB, CAROL F · 1999 to 2009
$2.4M
Understanding early events in lupus autoimmunity to aid preventionU01AI101934 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$2.3M
Functional Mechanisms of Causal Variants in Systemic Lupus ErythematosusR01AR063124 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2012 to 2016
$2.0M
Role of the transcription factor ARID3a in innate immune responsesR01AI118836 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WEBB, CAROL F · 2017 to 2020
$1.5M
Role of the transcription factor ARID3a in lupusR21AI090343 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI WEBB, CAROL F · 2010 to 2011
$430k
NIAID NIH HHS R01 AI044215NIAID NIH HHS R01 AI118836NIAID NIH HHS R21 AI090343NIAID NIH HHS R56 AI118836NIAID NIH HHS T32 AI007633NIAID NIH HHS U01 AI101934NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIAMS NIH HHS R01 AR056360NIAMS NIH HHS R01 AR063124NIGMS NIH HHS P30 GM103510NIGMS NIH HHS P30 GM110766NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Previously, we determined that enhanced disease activity in patients with systemic lupus erythematosus (SLE) was associated with dramatic increases in numbers of B lymphocytes expressing the transcription factor ARID3a. Our data now indicate ARID3a is important for interferon alpha (IFNa) expression and show a strong association between ARID3a expression and transcription of genes associated with lupus IFN signatures. Furthermore, both ARID3a and IFNa production were elicited in healthy control B cells upon stimulation with the TLR 9 agonist, CpG. Importantly, secretion of IFNa from ARID3a

Indexed as

B-Lymphocyte SubsetsCell Line, TumorCells, CulturedDendritic CellsDNA-Binding ProteinsFlow CytometryGene ExpressionHumansInterferon-alphaOligodeoxyribonucleotidesReverse Transcriptase Polymerase Chain ReactionToll-Like Receptor 9Transcription FactorsARID3A protein, humanDNA-Binding ProteinsInterferon-alphaOligodeoxyribonucleotidesProMuneToll-Like Receptor 9Transcription FactorsARID3aEffector B lymphocyteInflammationInterferon alphaLupus

Identifiers

PMID27522115
PMCPMC5134920
OpenAlexW2516617960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.